Drug Recalls Archives - Page 2 of 41

Valsartan Lawsuits

April 29, 2019 By Sandra Dalton Leave a Comment

Valsartan is the active pharmaceutical ingredient (API) in certain medications used to treat high blood pressure, congestive heart failure, and heart attack. It is sold in generic form and under the brand name Diovan. Valsartan is in a class of drugs called angiotensin II receptor blockers (ARBs). Valsartan produced by certain manufacturers, … [Read more...]

Drug Used to Treat Gout Is Dangerous, FDA Warns

April 23, 2019 By Lynn Fugaro Leave a Comment

On February 21, 2019, the Food and Drug Administration (FDA) posted the following urgent message on its website: “The FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an … [Read more...]

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets

December 4, 2018 By The FDA Leave a Comment

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg … [Read more...]

If Your Blood Pressure Medication was Recalled, Substitutes are Available

December 4, 2018 By Sandra Dalton Leave a Comment

If you take blood pressure medication, or any necessary medication, you need a backup plan in case yours is recalled. It’s not safe to just suddenly stop taking a drug used to control your high blood pressure, so talk to your doctor about the alternatives now. New medications keep getting added to the recall list. There were two just last week. The … [Read more...]

Highest Court in PA Set to Consider Tolling Statute of Limitations in Risperdal Cases

November 12, 2018 By Lynn Fugaro Leave a Comment

In July 2018, the Pennsylvania Supreme Court announced its decision to review a ruling by the Pennsylvania Court of Common Pleas regarding the statute of limitations in a case regarding the drug Risperdal. Essentially, the Supreme Court will have to decide whether the Court of Common Pleas was correct in dismissing the Plaintiffs’ case on summary … [Read more...]